NO20054223L - Antistoffmolekyler som har spesifisitet for human IL-1beta - Google Patents

Antistoffmolekyler som har spesifisitet for human IL-1beta

Info

Publication number
NO20054223L
NO20054223L NO20054223A NO20054223A NO20054223L NO 20054223 L NO20054223 L NO 20054223L NO 20054223 A NO20054223 A NO 20054223A NO 20054223 A NO20054223 A NO 20054223A NO 20054223 L NO20054223 L NO 20054223L
Authority
NO
Norway
Prior art keywords
specificity
beta
human
antibody molecules
antibody molecule
Prior art date
Application number
NO20054223A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054223D0 (no
Inventor
Andrew George Popplewell
Alastair David Griffith Lawson
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of NO20054223D0 publication Critical patent/NO20054223D0/no
Publication of NO20054223L publication Critical patent/NO20054223L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
NO20054223A 2003-02-13 2005-09-12 Antistoffmolekyler som har spesifisitet for human IL-1beta NO20054223L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0303337.0A GB0303337D0 (en) 2003-02-13 2003-02-13 Biological products
PCT/GB2004/000463 WO2004072116A2 (en) 2003-02-13 2004-02-06 ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-1β

Publications (2)

Publication Number Publication Date
NO20054223D0 NO20054223D0 (no) 2005-09-12
NO20054223L true NO20054223L (no) 2005-11-08

Family

ID=9952969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054223A NO20054223L (no) 2003-02-13 2005-09-12 Antistoffmolekyler som har spesifisitet for human IL-1beta

Country Status (26)

Country Link
US (2) US7608694B2 (el)
EP (2) EP1597282B1 (el)
JP (2) JP4668896B2 (el)
KR (1) KR20050099509A (el)
CN (1) CN1745103A (el)
AR (1) AR043159A1 (el)
AT (1) ATE525397T1 (el)
AU (1) AU2004210776B2 (el)
BR (1) BRPI0407233A (el)
CA (1) CA2515474C (el)
CL (1) CL2004000259A1 (el)
CY (1) CY1112507T1 (el)
DK (1) DK1597282T3 (el)
EA (1) EA200501286A1 (el)
EC (1) ECSP056014A (el)
ES (1) ES2373953T3 (el)
GB (1) GB0303337D0 (el)
IS (1) IS8013A (el)
MX (1) MXPA05007392A (el)
NO (1) NO20054223L (el)
PE (1) PE20040947A1 (el)
PL (1) PL378412A1 (el)
PT (1) PT1597282E (el)
SI (1) SI1597282T1 (el)
TW (1) TW200505942A (el)
WO (1) WO2004072116A2 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PL1899378T3 (pl) 2005-06-21 2011-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
EP3332807B1 (en) * 2005-10-26 2023-02-22 Novartis AG Use of anti il-1beta antibodies
CN101356194B (zh) 2005-12-09 2013-06-12 Ucb医药有限公司 对人il-6具有特异性的抗体分子
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
SI2125894T1 (sl) 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
NZ588850A (en) * 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
EP2341935A4 (en) 2008-09-05 2012-07-25 Xoma Technology Ltd METHODS FOR IMPROVING BETA CELL FUNCTION
MA33122B1 (fr) * 2009-02-17 2012-03-01 Ucb Pharma Sa Molecules d'anticorps ayant une specificite pour ox40 humain
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
PL2993231T3 (pl) 2009-09-24 2019-01-31 Ucb Biopharma Sprl Szczep bakteryjny do ekspresji rekombinowanego białka mający degp pozbawione aktywności proteazowej przy zachowaniu aktywności białka opiekuńczego i nokauty genów tsp i ptr
TW201124427A (en) * 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
JP5904645B2 (ja) 2010-05-07 2016-04-13 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連病態の治療のための方法
EP2571532B1 (en) 2010-05-14 2017-05-03 Abbvie Inc. Il-1 binding proteins
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
PT2731973T (pt) 2011-07-13 2018-02-22 Ucb Biopharma Sprl Estirpe hospedeira bacteriana que expressa dsbc recombinante
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
DK2814843T3 (da) 2012-02-13 2020-06-22 Agency Science Tech & Res IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
JP6397933B2 (ja) 2014-01-20 2018-09-26 ユーシービー バイオファルマ エスピーアールエル 固体形態の医薬組成物の再構成のための方法
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
US9560393B2 (en) * 2015-02-20 2017-01-31 Disney Enterprises, Inc. Media processing node
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
KR20180067676A (ko) 2015-10-27 2018-06-20 유씨비 바이오파마 에스피알엘 항-il-17a/f 항체를 사용한 치료 방법
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
US11976115B2 (en) * 2018-11-07 2024-05-07 Zeda Biopharmaceuticals, Inc. Antibody binding to human IL-1β, preparation method therefor and use thereof
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
AR124250A1 (es) 2020-12-07 2023-03-01 UCB Biopharma SRL Anticuerpos
AR125732A1 (es) 2021-05-03 2023-08-09 UCB Biopharma SRL Anticuerpos anti-trem1
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN113855807A (zh) * 2021-10-25 2021-12-31 孙良丹 一种试剂在制备治疗/抑制银屑病药物中的应用
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB129105A (en) 1918-07-02 1919-07-02 Alfred George Hubble Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels.
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1996022790A1 (en) 1995-01-23 1996-08-01 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
JPH09183799A (ja) * 1995-11-06 1997-07-15 Merck Patent Gmbh ヒト化モノクローナル抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2003010282A2 (en) * 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
PE20040947A1 (es) 2004-12-29
GB0303337D0 (en) 2003-03-19
EA200501286A1 (ru) 2006-02-24
SI1597282T1 (sl) 2012-02-29
NO20054223D0 (no) 2005-09-12
ECSP056014A (es) 2006-01-27
US8465744B2 (en) 2013-06-18
AR043159A1 (es) 2005-07-20
CY1112507T1 (el) 2015-12-09
PL378412A1 (pl) 2006-04-03
EP2287193A1 (en) 2011-02-23
US7608694B2 (en) 2009-10-27
ES2373953T3 (es) 2012-02-10
US20060228358A1 (en) 2006-10-12
EP1597282B1 (en) 2011-09-21
BRPI0407233A (pt) 2006-01-31
CA2515474C (en) 2013-11-12
MXPA05007392A (es) 2005-09-12
AU2004210776A1 (en) 2004-08-26
KR20050099509A (ko) 2005-10-13
TW200505942A (en) 2005-02-16
JP2007515925A (ja) 2007-06-21
WO2004072116A2 (en) 2004-08-26
IS8013A (is) 2005-09-07
JP2010246553A (ja) 2010-11-04
CN1745103A (zh) 2006-03-08
EP1597282A2 (en) 2005-11-23
CA2515474A1 (en) 2004-08-26
CL2004000259A1 (es) 2005-04-15
ATE525397T1 (de) 2011-10-15
DK1597282T3 (da) 2012-01-23
US20100158913A1 (en) 2010-06-24
WO2004072116A3 (en) 2004-11-18
AU2004210776B2 (en) 2011-04-07
JP4668896B2 (ja) 2011-04-13
PT1597282E (pt) 2012-01-05

Similar Documents

Publication Publication Date Title
NO20054223L (no) Antistoffmolekyler som har spesifisitet for human IL-1beta
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
TW200621801A (en) Antibody molecules having specificity for human IL-17
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
ATE364618T1 (de) Antikörper gegen das muc18-antigen
NO20054371L (no) Somatostatin-dopamin kimaere analoger
ME00425B (me) Liječenje sa anti-vegf antitijelima
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
NO20065859L (no) Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser
NO20055450L (no) Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon
ECSP055659A (es) Derivados de cicloalquilamina antidepresiva de benzodioxanos fusionados con heterociclos
ATE455789T1 (de) Substituierte nonadepsipeptide
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
DK1412503T3 (da) Et fusionsprotein
ATE410415T1 (de) Neue verbindungen
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6
EA200401523A1 (ru) Способы применения и композиции для диагностики и лечения инфекционного заболевания
DE60327896D1 (de) Einschlusskörper als antigene für die orale impfung von tieren gegen csfv
EA200701031A1 (ru) Молекулы, способствующие гематопоэзу
HN2003000273A (es) Derivados heterociclicos
TH71073A (th) แอนติบอดีโมเลกุลที่มีความจำเพาะสำหรับ il-1(เบตา) ของคน